The medical context for PTH at that time was dominated by the results of the clinical trial, which presented significant long-term efficacy and safety data in mid-2022.
Documents or data files from May 2022 often contain results from the trial, which evaluated TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. Key findings shared around this time included:
: The treatment was generally well-tolerated with no treatment-related serious or severe adverse events reported through the study period. 2022 05 13 PTh actualizat.rar
Below is a review of the likely clinical findings and relevance associated with PTH updates from that period:
: Significant improvements were noted in physical and cognitive symptoms as measured by the HPES (Hypoparathyroidism Patient Experience Scale) and SF-36 surveys. Interpreting PTH Updates The medical context for PTH at that time
: A "normal" PTH level can still be indicative of disease (such as primary hyperparathyroidism) if blood calcium is simultaneously high. Experts from Cleveland Clinic and MedlinePlus emphasize that PTH results must always be interpreted in direct context with calcium levels. Summary of PTH Relevance Parathyroid Hormone (PTH) Blood Test - UF Health
: Standard "normal" ranges for PTH are typically 10–65 pg/mL . However, mid-2022 research highlighted that these ranges often need adjustment based on age, BMI, and Vitamin D levels. Below is a review of the likely clinical
If this file is a laboratory or reference update, it likely addresses the ongoing challenges in :